Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Other Non Operating Income (2016 - 2026)

Sunshine Biopharma filings provide 11 years of Other Non Operating Income readings, the most recent being -$2.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 100.0% to -$2.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2642.0, a 105.99% increase, with the full-year FY2025 number at $2642.0, up 105.99% from a year prior.
  • Other Non Operating Income hit -$2.0 in Q4 2025 for Sunshine Biopharma, down from $253.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $286535.0 in Q2 2024 to a low of -$340003.0 in Q4 2024.
  • Median Other Non Operating Income over the past 5 years was $15.0 (2023), compared with a mean of -$4737.3.
  • The widest YoY moves for Other Non Operating Income: up 109883.52% in 2024, down 871702.56% in 2024.
  • Sunshine Biopharma's Other Non Operating Income stood at -$58890.0 in 2021, then skyrocketed by 99.12% to -$521.0 in 2022, then skyrocketed by 92.51% to -$39.0 in 2023, then plummeted by 871702.56% to -$340003.0 in 2024, then soared by 100.0% to -$2.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$2.0 (Q4 2025), $253.0 (Q3 2025), and $1940.0 (Q2 2025) per Business Quant data.